Claims for Patent: 9,782,414

Summary for Patent: 9,782,414

Title:	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Abstract:	A novel crystalline form of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.
Inventor(s):	Alisha B. Arrigo, Derrick Juengst, Khalid Shah
Assignee:	Array Biopharma Inc
Application Number:	US15/399,207
Patent Claims:	1. A method of treating cancer in a pediatric patient in need thereof, the method comprising: a) detecting a cancer in a pediatric patient that exhibits a dysregulation of a NTRK gene, a Trk protein, or expression or level of the same; and b) administering to the pediatric patient a therapeutically effective amount of a dosage form comprising a crystalline form (I-HS) having the formula wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2. 2. The method of claim 1, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2. 3. The method of claim 1, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 18.4±0.2, 19.2±0.2, 20.2±0.2, 20.7±0.2, 21.5±0.2, 23.1±0.2, and 24.0±0.2. 4. The method of claim 1, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 15.3±0.2, 16.5±0.2, 18.4±0.2, 19.2±0.2, 19.9±0.2, 20.2±0.2, 20.7±0.2, 21.5±0.2, 22.1±0.2, 23.1±0.2, 24.0±0.2, 24.4±0.2, 25.6±0.2, 26.5±0.2, 27.6±0.2, 28.2±0.2, 28.7±0.2, 30.8±0.2, and 38.5±0.2. 5. The method of claim 1, wherein the cancer is selected from the group consisting of pediatric glioma, infantile sarcoma, neuroblastoma, congenital mesoblastic nephroma (CMN), brain low-grade glioma, pontine glioma, secretory breast cancer, infantile fibrosarcoma (IFS), pediatric papillary thyroid cancer, and Ph-like acute lymphoblastic leukemia. 6. The method of claim 1, wherein the dysregulation of a NTRK gene, a Trk protein, or expression or level of the same results in the translation of a Trk fusion protein or mutation of a Trk kinase. 7. The method of claim 6, wherein the Trk fusion protein is selected from the group consisting of: TP53-TrkA, LMNA-TrkA, CD74-TrkA, TFG-TrkA, TPM3-TrkA, NFASC-TrkA, BCAN-TrkA, MPRIP-TrkA, TPR-TrkA, RFWD2-TrkA, IRF2BP2-TrkA, SQSTM1-TrkA, SSBP2-TrkA, RABGAP1L-TrkA, C18ORF8-TrkA, RNF213-TrkA, TBC1D22A-TrkA, C20ORF112-TrkA, DNER-TrkA, ARHGEF2-TrkA, CHTOP-TrkA, PPL-TrkA, PLEKHA6-TrkA, PEAR1-TrkA, MRPL24-TrkA, MDM4-TrkA, LRRC71-TrkA, GRIPAP1-TrkA, EPS15-TrkA, DYNC2H1-TrkA, CEL-TrkA, EPHB2-TrkA, TGF-TrkA, NACC2-TrkB, QKI-TrkB, AFAP1-TrkB, PAN3-TrkB, SQSTM1-TrkB, TRIM24-TrkB, VCL-TrkB, AGBL4-TrkB, DAB2IP-TrkB, ETV6-TrkC, BTBD1-TrkC, LYN-TrkC, RBPMS-TrkC, EML4-TrkC, HOMER2-TrkC, TFG-TrkC, FAT1-TrkC, and TEL-TrkC. 8. The method of claim 6, wherein the mutation is one or more point mutations in a NTRK1, NTRK2, or NTRK3 gene. 9. The method of claim 8, wherein the one or more point mutations results in the translation of a TrkA protein comprising an amino acid substitution at an amino acid position selected from the group consisting of 33, 336, 337, 324, 420, 444, 517, 538, 649, 682, 683, 702, and 1879. 10. The method of claim 9, wherein the one or more point mutations results in the translation of a TrkA protein comprising an amino acid substitution selected from the group consisting of R33W, A336E, A337T, R324Q, R324W, V420M, R444Q, R444W, G517R, G517V, K538A, R649W, R649L, R682S, V683G, R702C, and C1879T. 11. A method of treating cancer in a pediatric patient in need thereof, the method comprising: a) detecting a cancer in a pediatric patient that exhibits a dysregulation of a NTRK gene, a Trk protein, or expression or level of the same; and b) administering to the pediatric patient a therapeutically effective amount of a liquid formulation prepared from a crystalline form (I-HS) having the formula wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2. 12. The method of claim 11, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2. 13. The method of claim 11, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 18.4±0.2, 19.2±0.2, 20.2±0.2, 20.7±0.2, 21.5±0.2, 23.1±0.2, and 24.0±0.2. 14. The method of claim 11, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 15.3±0.2, 16.5±0.2, 18.4±0.2, 19.2±0.2, 19.9±0.2, 20.2±0.2, 20.7±0.2, 21.5±0.2, 22.1±0.2, 23.1±0.2, 24.0±0.2, 24.4±0.2, 25.6±0.2, 26.5±0.2, 27.6±0.2, 28.2±0.2, 28.7±0.2, 30.8±0.2, and 38.5±0.2. 15. The method of claim 11, wherein the cancer is selected from the group consisting of pediatric glioma, infantile sarcoma, neuroblastoma, congenital mesoblastic nephroma (CMN), brain low-grade glioma, pontine glioma, secretory breast cancer, infantile fibrosarcoma (IFS), pediatric papillary thyroid cancer, and Ph-like acute lymphoblastic leukemia. 16. The method of claim 11, wherein the dysregulation of a NTRK gene, a Trk protein, or expression or level of the same results in the translation of a Trk fusion protein or mutation of a Trk kinase. 17. The method of claim 16, wherein the Trk fusion protein is selected from the group consisting of: TP53-TrkA, LMNA-TrkA, CD74-TrkA, TFG-TrkA, TPM3-TrkA, NFASC-TrkA, BCAN-TrkA, MPRIP-TrkA, TPR-TrkA, RFWD2-TrkA, IRF2BP2-TrkA, SQSTM1-TrkA, SSBP2-TrkA, RABGAP1L-TrkA, C18ORF8-TrkA, RNF213-TrkA, TBC1D22A-TrkA, C20ORF112-TrkA, DNER-TrkA, ARHGEF2-TrkA, CHTOP-TrkA, PPL-TrkA, PLEKHA6-TrkA, PEAR1-TrkA, MRPL24-TrkA, MDM4-TrkA, LRRC71-TrkA, GRIPAP1-TrkA, EPS15-TrkA, DYNC2H1-TrkA, CEL-TrkA, EPHB2-TrkA, TGF-TrkA, NACC2-TrkB, QKI-TrkB, AFAP1-TrkB, PAN3-TrkB, SQSTM1-TrkB, TRIM24-TrkB, VCL-TrkB, AGBL4-TrkB, DAB2IP-TrkB, ETV6-TrkC, BTBD1-TrkC, LYN-TrkC, RBPMS-TrkC, EML4-TrkC, HOMER2-TrkC, TFG-TrkC, FAT1-TrkC, and TEL-TrkC. 18. The method of claim 16, wherein the mutation is one or more point mutations in a NTRK1, NTRK2, or NTRK3 gene. 19. The method of claim 18, wherein the one or more point mutations results in the translation of a TrkA protein comprising an amino acid substitution at an amino acid position selected from the group consisting of 33, 336, 337, 324, 420, 444, 517, 538, 649, 682, 683, 702, and 1879. 20. The method of claim 18, wherein the one or more point mutations results in the translation of a TrkA protein comprising an amino acid substitution selected from the group consisting of R33W, A336E, A337T, R324Q, R324W, V420M, R444Q, R444W, G517R, G517V, K538A, R649W, R649L, R682S, V683G, R702C, and C1879T. 21. A method of treating a cancer that exhibits a dysregulation of a NTRK gene, a Trk protein, or expression or level of the same in a pediatric patient in need thereof, the method comprising administering to the pediatric patient a therapeutically effective amount of a dosage form comprising a crystalline form (I-HS) having the formula wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2. 22. The method of claim 21, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2. 23. The method of claim 21, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 18.4±0.2, 19.2±0.2, 20.2±0.2, 20.7±0.2, 21.5±0.2, 23.1±0.2, and 24.0±0.2. 24. The method of claim 21, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 15.3±0.2, 16.5±0.2, 18.4±0.2, 19.2±0.2, 19.9±0.2, 20.2±0.2, 20.7±0.2, 21.5±0.2, 22.1±0.2, 23.1±0.2, 24.0±0.2, 24.4±0.2, 25.6±0.2, 26.5±0.2, 27.6±0.2, 28.2±0.2, 28.7±0.2, 30.8±0.2, and 38.5±0.2. 25. The method of claim 21, wherein the cancer is selected from the group consisting of pediatric glioma, infantile sarcoma, neuroblastoma, congenital mesoblastic nephroma (CMN), brain low-grade glioma, pontine glioma, secretory breast cancer, infantile fibrosarcoma (IFS), pediatric papillary thyroid cancer, and Ph-like acute lymphoblastic leukemia. 26. A method of treating a cancer that exhibits a dysregulation of a NTRK gene, a Trk protein, or expression or level of the same in a pediatric patient in need thereof, the method comprising administering to the pediatric patient a therapeutically effective amount of a liquid formulation prepared from a crystalline form (I-HS) having the formula wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2. 27. The method of claim 26, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2. 28. The method of claim 26, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 18.4±0.2, 19.2±0.2, 20.2±0.2, 20.7±0.2, 21.5±0.2, 23.1±0.2, and 24.0±0.2. 29. The method of claim 26, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at °2θ values of 10.7±0.2, 15.3±0.2, 16.5±0.2, 18.4±0.2, 19.2±0.2, 19.9±0.2, 20.2±0.2, 20.7±0.2, 21.5±0.2, 22.1±0.2, 23.1±0.2, 24.0±0.2, 24.4±0.2, 25.6±0.2, 26.5±0.2, 27.6±0.2, 28.2±0.2, 28.7±0.2, 30.8±0.2, and 38.5±0.2. 30. The method of claim 26, wherein the cancer is selected from the group consisting of pediatric glioma, infantile sarcoma, neuroblastoma, congenital mesoblastic nephroma (CMN), brain low-grade glioma, pontine glioma, secretory breast cancer, infantile fibrosarcoma (IFS), pediatric papillary thyroid cancer, and Ph-like acute lymphoblastic leukemia.